- Home
- SAVA vs BMN Comparison
SAVA vs BMN Comparison
Compare SAVA & BMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- BMN
- Stock Information
- Founded
- SAVA 1998
- BMN 2020
- Country
- SAVA United States
- BMN United States
- Employees
- SAVA N/A
- BMN 19800
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- BMN Trusts Except Educational Religious and Charitable
- Sector
- SAVA Health Care
- BMN Finance
- Exchange
- SAVA Nasdaq
- BMN Nasdaq
- Market Cap
- SAVA 134.2M
- BMN 154.9M
- IPO Year
- SAVA N/A
- BMN N/A
- Fundamental
- Price
- SAVA $2.59
- BMN $25.19
- Analyst Decision
- SAVA Buy
- BMN
- Analyst Count
- SAVA 3
- BMN 0
- Target Price
- SAVA $111.50
- BMN N/A
- AVG Volume (30 Days)
- SAVA 12.4M
- BMN 29.9K
- Earning Date
- SAVA 11-07-2024
- BMN 01-01-0001
- Dividend Yield
- SAVA N/A
- BMN 4.66%
- EPS Growth
- SAVA N/A
- BMN N/A
- EPS
- SAVA N/A
- BMN N/A
- Revenue
- SAVA N/A
- BMN N/A
- Revenue This Year
- SAVA N/A
- BMN N/A
- Revenue Next Year
- SAVA N/A
- BMN N/A
- P/E Ratio
- SAVA N/A
- BMN N/A
- Revenue Growth
- SAVA N/A
- BMN N/A
- 52 Week Low
- SAVA $2.55
- BMN $21.51
- 52 Week High
- SAVA $42.20
- BMN $25.59
- Technical
- Relative Strength Index (RSI)
- SAVA 23.06
- BMN 43.09
- Support Level
- SAVA $2.78
- BMN $25.15
- Resistance Level
- SAVA $3.28
- BMN $25.80
- Average True Range (ATR)
- SAVA 0.24
- BMN 0.33
- MACD
- SAVA 0.40
- BMN -0.05
- Stochastic Oscillator
- SAVA 4.73
- BMN 2.70
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
About BMN BlackRock 2037 Municipal Target Term Trust of Beneficial Interest
BlackRock 2037 Mun Tgt is a non-diversified, closed-end management investment company. The Trust's investment objective is to provide current income that is exempt from regular federal income tax. The Trust invests in investment grade quality securities or securities that are unrated but judged to be of comparable quality by the investment adviser.